Postibrutinib relapse outcomes for patients with marginal zone lymphoma

Epperla, Narendranath; Zhao, Qiuhong; Chowdhury, Sayan Mullick; Shea, Lauren; Moyo, Tamara K.; Reddy, Nishitha; Sheets, Julia; Weiner, David M.; Geethakumari, Praveen Ramakrishnan; Kandarpa, Malathi; Bruno, Ximena Jordan; Thomas, Cheddhi; Churnetski, Michael C.; Hsu, Andrew; Zurbriggen, Luke D.; Tan, Xiao-wei Cherie; Lindsey, Kathryn; Maakaron, Joseph; Caimi, Paolo; Torka, Pallawi; Bello, Celeste M.; Ayyappan, Sabarish; Oh, Timothy Seijung; Karmali, Reem; Kim, Seo‐Hyun; Kress, Anna; Kothari, Shalin; Sawalha, Yazeed; Christian, Beth; David, Kevin A.; Greenwell, Irl Brian; Janakiram, Murali; Kenkre, Vaishalee P.; Olszewski, Adam J.; Cohen, Jonathon B.; Palmisiano, Neil; Umyarova, Elvira; Wilcox, Ryan A.; Awan, Farrukh T.; Alderuccio, Juan Pablo; Barta, Stefan K.; Grover, Natalie S; Ghosh, Nilanjan; Bartlett, Nancy L.; Herrera, Alex F.; Shouse, Geoffrey

doi:10.1182/bloodadvances.2022008634

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the findings in a large multicenter retrospective study by Epperla et al. were consistent with those of the PCYC1121 study ( 37 , 38 ).…”

Section: Current Treatmentssupporting

confidence: 81%

Advances in the treatment of relapsed/refractory marginal zone lymphoma

Wang,

Wan,

Zhang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Marginal zone lymphoma (MZL) is the second most common subtype of inert B-cell non-Hodgkin’s lymphoma, accounting for 5–15% of non-Hodgkin’s lymphoma cases. Patients with MZL have a long survival period, with a median survival of >10 years, and patients treated with a combination of anti-CD20 monoclonal antibody can achieve an overall effective rate of 81%. However, 20% of patients with MZL show relapse or experience disease progression within 2 years, with a median survival of only 3–5 years. Currently, the treatment options for patients with relapsed/refractory (R/R) MZL are limited, underscoring the pressing need for novel therapeutic drugs. The advent of novel anti-CD20 monoclonal antibodies, small molecule kinase inhibitors, immunomodulators, and other therapeutic strategies has ushered in a new era in the treatment of R/R MZL. Our objective is to summarize the existing treatment strategies, including immunotherapy and the emergent targeted therapies, and to evaluate their effectiveness and safety in the management of R/R MZL. By doing so, we aim to provide a clear understanding of the therapeutic landscape for R/R MZL, and to guide future research directions toward improving the prognosis and quality of life for patients afflicted with this challenging disease.

show abstract

“…In addition, the findings in a large multicenter retrospective study by Epperla et al. were consistent with those of the PCYC1121 study ( 37 , 38 ).…”

Section: Current Treatmentssupporting

confidence: 81%